HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Industrial Cannabis/Industrial Hemp

714.505

-8.512-1.18%

Number of Gainers:- -

Number of Losers:5

Number of Flat:2

PE:- -

High:728.780

Open:725.318

Low:707.362

Close:723.017

Volume:89.77M

Turnover:141.39M

Market Cap:28.50B

Float Cap:28.50B

Loading ...

Sihuan Pharmaceutical Receives Chinese Regulatory Nod for Human Studies of Diabetes Drug

MT Newswires Live

BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For Ind

SIHUAN PHARM (00460): Subsidiary Huisheng Bio Receives IND Approval for Self-Developed GLP-1R/GCGR Dual-Target Innovative Drug P052 Injection

Sihuan Pharmaceutical - P052 Injection Independently Developed by Huisheng Biopharmaceutical Approved for Ind

THOMSON REUTERS

Evergreen Products Group H1 Revenue HKD 465.7 Million

THOMSON REUTERS

SIHUAN PHARM (00460): Medical Aesthetics Surge and Innovation Drug Monetization Drive Valuation Recovery

Sihuan Pharmaceutical Announces Spin-Off and Separate Listing of Xuanzhu Biopharm on Hong Kong Stock Exchange

MEILLEUREHEALTH (02327) Shareholder Transfers Shares from CITIC Securities Hong Kong to Minsheng Securities, Transfer Value HK$106 Million

BUZZ-Sihuan Pharma hits 3-1/2-year peak on share buyback, growth optimism

SIHUAN PHARM (00460) Repurchases 13.096 Million Shares for HK$19.572 Million on September 2

Sihuan Pharmaceutical Files Next Day Disclosure with HKEX, Announces Repurchase of 13,096,000 Shares at HKD 19.57 Million

Grandshores Technology Group Ltd. Announces Date for Annual General Meeting

Xuanzhu Biology Plans Hong Kong IPO, Receives CSRC Filing Notice

SIHUAN PHARM (00460) Plans to Establish AI R&D Company with Shenyuanzhi Pharmaceutical to Jointly Explore AI-Driven Medical Aesthetics Product Development

Sihuan Pharmaceutical Partners with dProtein to Launch AI-Driven Medical Aesthetic R&D Company

Sihuan Pharmaceutical - Jointly Established AI R+D Co With Units to Explore Development of AI-Driven Novel Medical Aesthetic Products

THOMSON REUTERS

SIHUAN PHARM (00460): Chen Yanling to be Appointed as Member of Nomination Committee

Sihuan Pharmaceutical Announces Ms. Chen Yanling's Appointment to Nomination Committee

BRIEF-Sihuan Pharmaceutical Posts H1 Gross Profit RMB757.3 Million

LifeTech Scientific Posts Sharp Drop in H1 Profit; Shares Lose 2%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1600/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1600","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1600\",,,,,undefined,":{"symbol":"BK1600","market":"HK","secType":"PLATE","nameCN":"Industrial Cannabis/Industrial Hemp","latestPrice":714.50525,"timestamp":1757405290965,"preClose":723.0172,"halted":0,"volume":89770550,"delay":0,"changeRate":-0.011773,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-8.511963,"latestTime":"09-09 16:00:00","open":725.31824,"high":728.78033,"low":707.36163,"amount":141385413,"amplitude":0.029624,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"pbRate":2.479452,"peRate":-1857.956325,"turnoverRate":0.003092,"increases":1,"decrements":5,"flats":1,"marketCap":28501194392,"floatMarketCap":28501194392},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1600\",,,,,undefined,":{"symbol":"BK1600","high":728.78033,"amplitude":0.029624,"preClose":723.0172,"low":707.36163,"pbRate":"2.479452","latestPrice":714.50525,"volume":89770550,"delay":0,"open":725.31824,"prevYearClose":390.2235,"prevWeekClose":716.529,"prevMonthClose":668.528,"prevQuarterClose":606.888,"fiveDayClose":684.479,"twentyDayClose":672.387,"sixtyDayClose":596.611,"secType":"PLATE","market":"HK","turnoverRate":0.003092,"peRate":-1857.956325,"marketCap":28501194392,"floatMarketCap":28501194392,"timestamp":1757405290965,"nameCN":"Industrial Cannabis/Industrial Hemp"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1600\",,,,undefined,":{"bkCode":"BK1600","up":0,"down":5,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1600\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566652502","title":"Sihuan Pharmaceutical Receives Chinese Regulatory Nod for Human Studies of Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2566652502","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566652502?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:31","pubTimestamp":1757385061,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical  said Chinese regulators approved its experimental P052 injection for human studies, according to a Hong Kong bourse filing Tuesday.The company is developing P052 as a treatment for type 2 diabetes and obesity.The drug has a mechanism similar to Novo Nordisk's semaglutide.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2566965651","title":"BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2566965651","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566965651?lang=en_us&edition=fundamental","pubTime":"2025-09-09 09:33","pubTimestamp":1757381597,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For IndSept 9 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:P052 INJECTION INDEPENDENTLY DEVELOPED BY HUISHENG BIOPHARMACEUTICAL APPROVED FOR INDFurther company coverage: 0460.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UV1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","00460","BK1191","BK1593"],"gpt_icon":0},{"id":"1131898226","title":"SIHUAN PHARM (00460): Subsidiary Huisheng Bio Receives IND Approval for Self-Developed GLP-1R/GCGR Dual-Target Innovative Drug P052 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1131898226","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131898226?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:16","pubTimestamp":1757376982,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that its non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd. (Huisheng Bio), has received tacit approval from the Center for Drug Evaluation (CDE) of the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","06978","BK1574","BK1515","BK1593","BK4590","BK1600","GLP","159992","BK4144","00460"],"gpt_icon":0},{"id":"2566653655","title":"Sihuan Pharmaceutical - P052 Injection Independently Developed by Huisheng Biopharmaceutical Approved for Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2566653655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566653655?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:02","pubTimestamp":1757376174,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UV1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1191","BK1515","00460","BK1600"],"gpt_icon":0},{"id":"2565501008","title":"Evergreen Products Group H1 Revenue HKD 465.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2565501008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565501008?lang=en_us&edition=fundamental","pubTime":"2025-09-08 16:41","pubTimestamp":1757320868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nPLX0CAA97:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1600","01962","BK1585","BK1207"],"gpt_icon":0},{"id":"1124538763","title":"SIHUAN PHARM (00460): Medical Aesthetics Surge and Innovation Drug Monetization Drive Valuation Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=1124538763","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124538763?lang=en_us&edition=fundamental","pubTime":"2025-09-05 09:03","pubTimestamp":1757034204,"startTime":"0","endTime":"0","summary":"Southbound capital continues its robust influx into Hong Kong stocks, establishing the market as Asia's capital reservoir. According to Wind data, as of September 3, 2025, southbound funds through...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1600","BK1574","159992","BK1191","BK1161","BK1593","00460","BK1515"],"gpt_icon":0},{"id":"2564087413","title":"Sihuan Pharmaceutical Announces Spin-Off and Separate Listing of Xuanzhu Biopharm on Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2564087413","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564087413?lang=en_us&edition=fundamental","pubTime":"2025-09-04 22:25","pubTimestamp":1756995902,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. has announced the spin-off and separate listing of Xuanzhu Biopharmaceutical Co., Ltd. on the Main Board of the Stock Exchange of Hong Kong Limited. The listing involves SpinCo H Shares, which are overseas listed foreign shares in the ordinary share capital of Xuanzhu Biopharm, with a nominal value of RMB1.00 each. These shares are to be subscribed for and traded in Hong Kong dollars. The Record Date for determining Qualifying Shareholders' assured entitlement to the SpinCo Shares in the Global Offering is set for September 18, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on Septemb","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL8P26TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","00460","BK1191","BK1593"],"gpt_icon":0},{"id":"1108850124","title":"MEILLEUREHEALTH (02327) Shareholder Transfers Shares from CITIC Securities Hong Kong to Minsheng Securities, Transfer Value HK$106 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1108850124","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108850124?lang=en_us&edition=fundamental","pubTime":"2025-09-04 08:28","pubTimestamp":1756945701,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on September 3, a shareholder of MEILLEUREHEALTH (02327) transferred shares from CITIC Securities Hong Kong to Minsheng Securities,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","BK0028","LU1328615791.USD","LU2289578879.USD","LU1655091616.SGD","BK0276","BK0012","LU0405327494.USD","LU2495084118.USD","BK1124","LU0405327148.USD","06030","LU1064130708.USD","LU1720050803.USD","BK1516","LU1064131003.USD","BK1147","BK0196","BK0188","02327","600030","BK0183","LU1997245094.SGD","BK1521","LU1794554557.SGD","LU1997245177.USD","BK1564","LU2148510915.USD","161027","BK1600","LU1255011170.USD"],"gpt_icon":0},{"id":"2564353887","title":"BUZZ-Sihuan Pharma hits 3-1/2-year peak on share buyback, growth optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2564353887","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564353887?lang=en_us&edition=fundamental","pubTime":"2025-09-03 10:22","pubTimestamp":1756866138,"startTime":"0","endTime":"0","summary":"BUZZ-Sihuan Pharma hits 3-1/2-year peak on share buyback, growth optimism ** Shares of Sihuan Pharmaceutical Holdings Group 0460.HK jump 9.3% to HK$1.64, their highest level since February 2022 ** Stock marks its biggest intraday pct rise since July 14, and is second-biggest pct gainer in the healthcare index .HSCIH, which rises 1.6% ** Company said it had on September 2 repurchased 13.1 million shares in the open market at an average price of HK$1.4945 apiece for HK$19.6 million  ** Sihuan says it has made positive progresses in new businesses of medical aesthetics and innovative pharmaceuticals and it expects launch of a large number of flagship new products to bring strong momentum to future revenue and profit growth** Hang Seng Biotech Index .HSHKBIO rises 1.7%, benchmark Hang Seng Index .HSI adds 0.03%** YTD, Sihuan stock up 143.9%, Hang Seng Index up 27.2%     ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nL1N3UQ01N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"1166044561","title":"SIHUAN PHARM (00460) Repurchases 13.096 Million Shares for HK$19.572 Million on September 2","url":"https://stock-news.laohu8.com/highlight/detail?id=1166044561","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166044561?lang=en_us&edition=fundamental","pubTime":"2025-09-02 17:46","pubTimestamp":1756806375,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that on September 2, 2025, the company spent HK$19.572 million to repurchase 13.096 million shares at prices ranging from HK$1.48 to HK$1.51 per share.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","BK1515","BK1593","BK1600"],"gpt_icon":0},{"id":"2564430808","title":"Sihuan Pharmaceutical Files Next Day Disclosure with HKEX, Announces Repurchase of 13,096,000 Shares at HKD 19.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2564430808","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564430808?lang=en_us&edition=fundamental","pubTime":"2025-09-02 17:41","pubTimestamp":1756806107,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange. The company reported the repurchase of 13,096,000 ordinary shares, held as treasury shares, at an aggregate price of HKD 19,571,972, with a volume-weighted average repurchase price per share of HKD 1.4945.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL9MQKl7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","BK1593","BK1191","00460"],"gpt_icon":0},{"id":"2564087066","title":"Grandshores Technology Group Ltd. Announces Date for Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2564087066","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564087066?lang=en_us&edition=fundamental","pubTime":"2025-09-02 17:15","pubTimestamp":1756804518,"startTime":"0","endTime":"0","summary":"Grandshores Technology Group Limited is set to hold its annual general meeting on 26 September 2025. The meeting will take place at the United Centre in Hong Kong. During the meeting, shareholders will consider and vote on several key proposals, including the granting of general mandates to issue new shares and repurchase shares, as well as the re-election of directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grandshores Technology Group Ltd. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL3fYJ2z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1612","BK1148","BK1600","01647"],"gpt_icon":0},{"id":"1161323446","title":"Xuanzhu Biology Plans Hong Kong IPO, Receives CSRC Filing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=1161323446","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161323446?lang=en_us&edition=fundamental","pubTime":"2025-09-01 13:30","pubTimestamp":1756704630,"startTime":"0","endTime":"0","summary":"On August 29, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice for Xuanzhu Biotech Co., Ltd.'s overseas issuance and listing and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","BK1191","BK1593","00460"],"gpt_icon":0},{"id":"1110221219","title":"SIHUAN PHARM (00460) Plans to Establish AI R&D Company with Shenyuanzhi Pharmaceutical to Jointly Explore AI-Driven Medical Aesthetics Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1110221219","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110221219?lang=en_us&edition=fundamental","pubTime":"2025-09-01 12:12","pubTimestamp":1756699957,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that to promote the deep application and industrialization of artificial intelligence (AI) technology in medical aesthetics product research and development, the group...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","BK1593","BK1600","BK1515"],"gpt_icon":0},{"id":"2564860730","title":"Sihuan Pharmaceutical Partners with dProtein to Launch AI-Driven Medical Aesthetic R&D Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2564860730","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564860730?lang=en_us&edition=fundamental","pubTime":"2025-09-01 12:06","pubTimestamp":1756699565,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. has entered into a strategic partnership with dProtein Pharmaceutical Biotechnology  Co., Ltd. to establish an AI R&D company. This collaboration aims to explore the development of innovative medical aesthetic products driven by artificial intelligence technology. The joint venture marks a significant step in Sihuan Pharmaceutical's strategic direction to integrate AI within the medical aesthetic industry, enhancing its competitiveness and market value. Through this alliance, both parties intend to harness technological innovation to meet the growing demands of the medical aesthetic market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the or","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nNDL9fbw4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","BK1593","BK1600","BK1515"],"gpt_icon":0},{"id":"2564860245","title":"Sihuan Pharmaceutical - Jointly Established AI R+D Co With Units to Explore Development of AI-Driven Novel Medical Aesthetic Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2564860245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564860245?lang=en_us&edition=fundamental","pubTime":"2025-09-01 12:02","pubTimestamp":1756699324,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250901:nFWN3UL1GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1600","BK1593","BK1191","00460"],"gpt_icon":0},{"id":"1175605827","title":"SIHUAN PHARM (00460): Chen Yanling to be Appointed as Member of Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=1175605827","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175605827?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:40","pubTimestamp":1756460416,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that Ms. Chen Yanling, the company's current executive director, will be appointed as a member of the company's nomination committee, effective from September 1, 2025.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2563048606","title":"Sihuan Pharmaceutical Announces Ms. Chen Yanling's Appointment to Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2563048606","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563048606?lang=en_us&edition=fundamental","pubTime":"2025-08-29 17:17","pubTimestamp":1756459054,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. announced a change in the composition of its Nomination Committee. Ms. Chen Yanling, an existing executive director, will be appointed as a member of the committee, effective September 1, 2025. The Nomination Committee will continue to have a majority of independent non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL4V8SpS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK1600","00460","BK1191"],"gpt_icon":0},{"id":"2563901238","title":"BRIEF-Sihuan Pharmaceutical Posts H1 Gross Profit RMB757.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563901238","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563901238?lang=en_us&edition=fundamental","pubTime":"2025-08-29 16:12","pubTimestamp":1756455151,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharmaceutical Posts H1 Gross Profit RMB757.3 MillionAug 29  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:H1 GROSS PROFIT RMB 757.3 MILLIONH1 GROSS MARGIN 66.1%H1 PRETAX PROFIT RMB 156.9 MILLIONH1 REVENUE RMB 1,146.2 MILLIONH1 OPERATING PROFIT RMB 264.4 MILLIONRESOLVED TO DECLARE AN INTERIM CASH DIVIDEND OF RMB0.99 CENTS PER SHAREFurther company coverage: 0460.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nPLXA63585:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2563134580","title":"LifeTech Scientific Posts Sharp Drop in H1 Profit; Shares Lose 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563134580","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563134580?lang=en_us&edition=fundamental","pubTime":"2025-08-29 13:47","pubTimestamp":1756446469,"startTime":"0","endTime":"0","summary":"LifeTech Scientific  reported a profit attributable to owners of 55.1 million yuan for the first half of 2025, down from 205.6 million yuan a year earlier, according to a Friday Hong Kong bourse filing.Earnings per share came in at 0.013 yuan, compared with 0.046 yuan in the prior-year period.Revenue rose to 676.7 million yuan from 652.8 million yuan.The board did not recommend an interim dividend.Shares of the medical device manufacturer were down nearly 2% in Friday afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1100","01302","BK1600","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}